Events

30 November - 2 December | Boston, USA

2 - 4 November | Basel, Switzerland

Novel biomarkers of immunotherapy outcomes and immune-related adverse events.

Oncimmune CEO, Dr Adam M Hill presents progress on the Company's three year strategy.

Shares Spotlight webinars feature presentations from directors of listed companies explaining their investment propositions followed by an opportunity for you to ask questions.

Professor Jessica Hassel presented the findings from 'Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasised melanoma'. This was the first time that the clinical utility of autoantibodies was presented at this prestigious international cancer research conference.